Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evogene Q3 2024 GAAP EPS $(1.31) Misses $(0.63) Estimate, Sales $1.80M Miss $2.85M Estimate

Author: Benzinga Newsdesk | November 21, 2024 07:33am
Evogene (NASDAQ:EVGN) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.63) by 107.94 percent. The company reported quarterly sales of $1.80 million which missed the analyst consensus estimate of $2.85 million by 36.98 percent. This is a 52.32 percent decrease over sales of $3.77 million the same period last year.

Posted In: EVGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist